Status: Not yet recruiting
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
This is a phase II, multicenter, single-arm, non-blind study. To 21 patients with PD-L1 ≥50% locally advanced non-small cell lung cancer, the combination of Pembrolizumab and platinum-doublets will be intravenously administered without radiotherapy to evaluate the efficacy and safety of combination therapy with Pembrolizumab and platinum-doublets.
Participants needed: 21
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: Kobe Minimally Invasive Cancer CenterUpdated: Nov 6, 2019
Eligibility criteria
Histologically confirmed NSCLC [+10]
A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocat... [+17]